Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Sintilimab，regofinib，cetuximab
KRAS BRAF mutant Sintilimab + regafinil
Locations
1
China
Rui Liu
Tianjin, Tianjin Municipality, China
Start Date
March 1, 2021
Primary Completion Date
February 1, 2023
Completion Date
January 1, 2024
Last Updated
February 14, 2023
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions